Exploring anti-TGF-β therapies in cancer and fibrosis
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Transforming growth factor-β (TGF-β) is a multifunctional cytokine, with important roles in maintaining tissue homeostasis. TGF-β signals via transmembrane serine/threonine kinase receptors and intracellular Smad transcriptional regulators. Perturbed TGF-β signaling has been implicated in a large variety of pathological conditions. Increased TGF-β levels have been found in patients with cancer, fibrosis, and systemic sclerosis, and were correlated with disease severity. In cancer, TGF-β mediates tumor invasion and metastasis by affecting both tumor cells and the tumor microenvironment including fibroblast activation and immune suppression. Furthermore, TGF-β is a strong stimulator of extracellular matrix deposition. On the basis of these observations, small molecule inhibitors of the TGF-β receptor kinases, neutralizing antibodies that interfere with ligand?receptor interactions, antisense oligonucleotides reducing TGF-β expression, and soluble receptor ectodomains that sequester TGF-β have been developed to intervene with excessive TGF-β signaling activity in the aforementioned disorders. Here, we review the current state of anti-TGF-β therapy in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907 · cited 3×
“…cancer, clinical trial TGF-b signaling and receptors The transforming growth factor-b (TGF-b) superfamily consists of 33 different pleiotropic cytokines that influence cell proliferation, migration, and differentiation (Massague 2008; Padua and Massague 2009; Meulmeester and ten Dijke 2011).”
BackgroundMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275 · cited 1×
“This small latent complex can be covalently bound to the latent TGF-b binding protein (LTBP) and stored in the extracellular matrix (ECM; Derynck et al. 2001; Koli et al. 2001; Maeda et al. 2002; Prud’homme 2007; ten Dijke and Arthur 2007).”
BackgroundMyofibroblast contraction activates latent TGF-β1 from the extracellular matrix
Wipff, P.-J., Rifkin, D. B., Meister, J.-J., & Hinz, B. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200704042 · Cited by 1,346 · cited 1×
“Proteolytic cleavage of the LTBP by (matrix metallo) proteinases followed by a second activation step, involving an integrinmediated conformational change to release mature TGF-b from the LAP, generates active TGF-b (Annes et al. 2003; Wipff et al. 2007).”
BackgroundTGF- β signaling in cancer – a double-edged sword
Akhurst, R. J., & Derynck, R. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02130-4 · Cited by 756
Denton (2007) · doi:10.1002/art.22289 · Cited by 447 · cited 1×
“In a phase I/II trial CAT-192, a TGF-b1 neutralizing antibody did not show effect on early stage diffuse cutaneous systemic sclerosis, together with more adverse events in the CAT-192-treated groups (Denton et al. 2007).”
BackgroundBogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq142 · Cited by 433
Yang, Y.-A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215333 · Cited by 404
Halder, S. K., Beauchamp, R. D., & Datta, P. K. (2005) · Neoplasia · doi:10.1593/neo.04640 · Cited by 288 · cited 1×
“Inhibition of TGF-b signaling by SB431542, a small molecule ALK-5 kinase inhibitor (Halder et al. 2005), in MCF10 breast cancer cells, inhibits their migration and invasion in collagen matrices via regulation of protease expression (Wiercinska et al. 2010).”
BackgroundNemunaitis, J., Nemunaitis, M., Senzer, N., Snitz, P., Bedell, C., Kumar, P., Pappen, B., Maples, P. B., Shawler, D., & Fakhrai, H. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.15 · Cited by 147
Cited by
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
Transforming growth factor–β in tissue fibrosis
Frangogiannis, N. G. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190103 · Cited by 1,278
Cytokine patterns in patients with cancer: a systematic review
Lippitz, B. E. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70582-x · Cited by 905
TGF-β in progression of liver disease
Dooley, S., & ten Dijke, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1246-y · Cited by 718
Myofibroblast-mediated mechanisms of pathological remodelling of the heart
Weber, K. T., Sun, Y., Bhattacharya, S. K., Ahokas, R. A., & Gerling, I. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.158 · Cited by 673
Metadata
- Authors
- Hawinkels, L. J. A. C., & ten Dijke, P.
- Venue
- Growth Factors
- Publisher
- Informa UK Limited
- Published
- 2011-06-30
- Volume
- 29
- Issue
- 4
- Pages
- 140-152
- ISSN
- 0897-7194 (ISSN-L)
- 1029-2292
- OpenAlex
- W2017410696
- Cited by
- 145
- References
- 15
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exploring anti-TGF-β therapies in cancer and fibrosis. https://app.cochat.ai/papers/10.3109/08977194.2011.595411
- The paper
- Hawinkels, L. J. A. C., & ten Dijke, P. (2011). Exploring anti-TGF-β therapies in cancer and fibrosis. Growth Factors. https://doi.org/10.3109/08977194.2011.595411
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.